Abstract:RNA editing offers the opportunity to introduce either stable or transient modifications to nucleic acid sequence without permanent off-target effects, but installation of arbitrary edits into the transcriptome is currently infeasible. Here, we describe Programmable RNA Editing & Cleavage for Insertion, Substitution, and Erasure (PRECISE), a versatile RNA editing method for writing RNA of arbitrary length and sequence into existing pre-mRNAs via 5′ or 3′ trans-splicing. In trans-splicing, an exogenous template is introduced to compete with the endogenous pre-mRNA, allowing for replacement of upstream or downstream exon sequence. Using Cas7-11 cleavage of pre-mRNAs to bias towards editing outcomes, we boost the efficiency of RNA trans-splicing by 10–100 fold, achieving editing rates between 5–50% and 85% on endogenous and reporter transcripts, respectively, while maintaining high-fidelity. We demonstrate PRECISE editing across 11 distinct endogenous transcripts of widely varying expression levels, showcasing more than 50 types of edits, including all 12 possible transversions and transitions, insertions ranging from 1 to 1,863 nucleotides, and deletions. We show high efficiency replacement of exon 4 of MECP2, addressing most mutations that drive the Rett Syndrome; editing of SHANK3 transcripts, a gene involved in Autism; and replacement of exon 1 of HTT, removing the hallmark repeat expansions of Huntington′s disease. Whole transcriptome sequencing reveals the high precision of PRECISE editing and lack of off-target trans-splicing activity. Furthermore, we combine payload engineering and ribozymes for protein-free, high-efficiency trans-splicing, with demonstrated efficiency in editing HTT exon 1 via AAV delivery. We show that the high activity of PRECISE editing enables editing in non-dividing neurons and patient-derived Huntington’s disease fibroblasts. PRECISE editing markedly broadens the scope of genetic editing, is straightforward to deliver over existing gene editing tools like prime editing, lacks permanent off-targets, and can enable any type of genetic edit large or small, including edits not otherwise possible with existing RNA base editors, widening the spectrum of addressable diseases.

Pentatricopeptide Repeat-directed RNA Editing and Their Biomedical Applications

Pentatricopeptide repeat proteins: II. Present status and future prospects of PPR-based programmable RNA editing in crop improvement

Research Progress on Relationship of PPR Proteins with RNA Editing

RNA editing enzymes: structure, biological functions and applications

RNA base editing in plant organelles with engineered synthetic P-type PPR editing factors

Site-directed RNA editing: recent advances and open challenges

RNA Editing of Nuclear Transcripts in Arabidopsis Thaliana

RNA editing machinery in plant organelles

RNA editing in the forefront of epitranscriptomics and human health

Programmable System of Cas13-Mediated RNA Modification and Its Biological and Biomedical Applications

The Role of RNA Editing in Cancer Development and Metabolic Disorders

Precision RNA base editing with engineered and endogenous effectors

CRISPR-Cas13: Pioneering RNA Editing for Nucleic Acid Therapeutics

Programmable RNA base editing via targeted modifications

Programmable RNA writing with trans-splicing

RNA Editors, Cofactors, and mRNA Targets: An Overview of the C-to-U RNA Editing Machinery and Its Implication in Human Disease

The Rice Pentatricopeptide Repeat Protein PPR756 Is Involved in Pollen Development by Affecting Multiple RNA Editing in Mitochondria

A plant pentatricopeptide repeat protein with a DYW-deaminase domain is sufficient for catalyzing C-to-U RNA editing in vitro

RNA Base Editors: the Emerging Approach of RNA Therapeutics.

RNA Editing as a Therapeutic Approach for Retinal Gene Therapy Requiring Long Coding Sequences

Robust RNA editing via recruitment of endogenous ADARs using circular guide RNAs